Anti-obesity drugs currently used and new compounds in clinical development

doi:10.13105/wjma.v2.i4.135

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14967)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-1) series.

Item

Count

PDF

687

WORD

1281

HTML

8683

Figures (1-6)

394

Tables (1-1)

160

Sum=11205

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

611

Download

1018

Sum=1629

Publishing Process of This Article

Item

Count

Browse

1025

Download

1108

Sum=2133

Nov 26, 2014 (publication date) through Jul 23, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Meta-Analysis

ISSN

2308-3840

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Meta-Anal. Nov 26, 2014; 2(4): 135-153
Published online Nov 26, 2014. doi: 10.13105/wjma.v2.i4.135

Full Size Figure Download Figure

Figure 4 Action of the orexigenic and anorexigenic hormones in the fasting and feeding states. AgRP: Agouti-related protein; GLP-1: Glucagon-like peptide-1; NPY: Neuropeptide Y; PYY: Peptide tyrosine-tyrosine; POMC: Pro-opiomelanocortin.

Citation: Martins A, Morgado S, Morgado M. Anti-obesity drugs currently used and new compounds in clinical development. World J Meta-Anal 2014; 2(4): 135-153
URL: https://www.wjgnet.com/2308-3840/full/v2/i4/135.htm
DOI: https://dx.doi.org/10.13105/wjma.v2.i4.135